Carcinoma Non-small-cell Lung
📧 Sign up to get email alerts when something new happens for Carcinoma Non-small-cell Lung.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Krazati (adagrasib) — Bristol-Myers Squibb Pharma EEIG
Authorised approval of Krazati (adagrasib) for non-small cell lung carcinoma by EMA, issued to Bristol-Myers Squibb Pharma EEIG with conditi…
-
EMA approval · 2026-08-18EMA Authorised: Alimta (pemetrexed) — Eli Lilly Nederland B.V.
European Medicines Agency authorises Alimta (pemetrexed) for mesothelioma and non-small-cell lung carcinoma.
-
EMA approval · 2026-08-06EMA Authorised: Docetaxel Kabi (docetaxel) — Fresenius Kabi Deutschland GmbH
EU authorization of Docetaxel Kabi (docetaxel) for multiple cancer indications including head and neck neoplasms, non-small cell lung carcin…
-
EMA approval · 2026-07-13EMA Authorised: Hetronifly (serplulimab) — Accord Healthcare S.L.U.
European Medicines Agency authorises Hetronifly (serplulimab) for multiple indications including small cell lung cancer, non-small cell lung…
-
EMA approval · 2026-07-07EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorises a biosimilar version of bevacizumab (Abevmy) for multiple cancer indications, expanding access to this biologic therapy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-01EMA Authorised: Hetronifly (serplulimab) — Accord Healthcare S.L.U.
European Medicines Agency authorises Hetronifly (serplulimab) for multiple indications including small cell lung cancer, non-small cell lung…
-
EMA approval · 2026-06-24EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG
Authorised approval for Yervoy (ipilimumab) with multiple indications including melanoma and various carcinomas and mesothelioma; decision d…
-
CLINICAL_TRIALS trial_result · 2024-11-19Clinical Trial Update: A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread [Phase 1]
A Phase 1 trial evaluating the safe dose of BI 891065 alone and in combination with BI 754091 in patients with incurable or metastatic tumor…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC [Phase 2]
A Phase 2 clinical trial evaluating SHR-1210 in patients with advanced or metastatic non-small cell lung cancer is listed, with current stat…
-
CLINICAL_TRIALS trial_result · 2022-11-07Clinical Trial Update: Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy [Phase 1, Phase 2]
Phase 1/2 trial update for Rhenium Re-188 P2045 in patients with lung cancer, including non-small cell and small cell types, who have had pr…
-
EMA withdrawal · 2021-12-14EMA Withdrawn: Docetaxel Teva (docetaxel) — Teva B.V.
The EMA has withdrawn Docetaxel Teva, an injectable chemotherapy containing docetaxel, from the European market.
-
EMA withdrawal · 2021-11-25EMA Withdrawn: Equidacent (bevacizumab) — Centus Biotherapeutics Europe Limited
Equidacent (bevacizumab) has been withdrawn from the market in the European Medicines Agency record.
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery [Phase 4]
Phase 4 trial update on dexamethasone and flurbiprofen axetil for delirium after lung cancer surgery; the study status is terminated.
-
CLINICAL_TRIALS trial_result · 2020-03-19Clinical Trial Update: Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer [Phase 3]
A Phase 3 trial evaluating FKB238 in combination with Avastin for advanced/recurrent non-squamous non-small cell lung cancer has completed w…
-
CLINICAL_TRIALS trial_result · 2020-03-02Clinical Trial Update: Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer [Phase 3]
Phase 3 trial comparing post-operative pain and quality of life after subxiphoid versus intercostal VATS in lung cancer patients has complet…
-
CLINICAL_TRIALS trial_result · 2019-12-27Clinical Trial Update: A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body [Phase 1]
Phase 1 trial of LY3009120 in advanced/metastatic cancer was terminated; results posted in 2019.
-
EMA withdrawal · 2019-10-15EMA Withdrawn: Taxespira (previously Docetaxel Hospira UK Limited ) (docetaxel trihydrate) — Hospira UK Limited
The EMA withdrew Taxespira (docetaxel trihydrate) from the market for multiple cancer indications including stomach, prostate, breast, head …
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases [Phase 2, Phase 3]
A phase 2/3 trial comparing conventional care to radioablation (stereotactic body radiotherapy) for extracranial oligometastases; status is …
-
CLINICAL_TRIALS trial_result · 2019-03-05Clinical Trial Update: Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery [Phase 4]
Phase 4 clinical trial update on dexamethasone and flurbiprofen axetil and their association with long-term survival after lung cancer surge…
-
EMA approval · 2017-11-30EMA Refused: Adlumiz (anamorelin hydrochloride) — Helsinn Birex Pharmaceuticals Ltd.
EMA refused Adlumiz (anamorelin hydrochloride) from Helsinn Birex Pharmaceuticals Ltd., a decision affecting its use for cachexia/anorexia i…
-
CLINICAL_TRIALS trial_result · 2017-06-21Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) [Phase 1, Phase 2]
Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of brigatinib (AP26113) in lympho…
-
EMA withdrawal · 2016-09-29EMA Application withdrawn: Docetaxel SUN — Sun Pharmaceutical Industries Europe B.V.
The EMA withdrew the application for Docetaxel SUN by Sun Pharmaceutical Industries Europe B.V. for multiple cancer indications.
-
CLINICAL_TRIALS trial_result · 2016-06-24Clinical Trial Update: A Study Of PF-06263507 In Patients With Advanced Solid Tumors [Phase 1]
Phase 1 trial of PF-06263507 in advanced solid tumors has been terminated; results posted.
-
EMA withdrawal · 2012-06-14EMA Withdrawn: Docefrez (docetaxel) — Sun Pharmaceutical Industries Europe B.V.
Withdrawn EMA entry for Docefrez (docetaxel) by Sun Pharmaceutical Industries Europe B.V.; listed indications include stomach neoplasms, ade…
-
EMA withdrawal · 2009-10-30EMA Application withdrawn: Zactima (vandetanib) — AstraZeneca
The EMA withdrew the application for Zactima (vandetanib) by AstraZeneca for non-small cell lung carcinoma.